BNGONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Bionano Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.22−0.03 (-2.40%)
Close on Oct 19, 2026
- Market cap
- $14.09M
- P/E (TTM)
- –
- Dividend yield
- –
Bionano Genomics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $7.69M | $6.09M | $7.50M | $6.93M | $6.31M | $6.00M | $7.65M | $6.02M | $6.51M | $6.83M | $8.22M | $6.46M | 94.2% | +21.9% |
| Consumables | $4.29M | $3.90M | $3.67M | $3.77M | $3.28M | $3.25M | $3.41M | $3.33M | $2.57M | $3.46M | $3.49M | $2.48M | 52.4% | +30.8% |
| Instruments | $2.04M | $962.00K | $2.66M | $1.62M | $1.40M | $689.00K | $2.75M | $1.42M | $2.26M | $1.61M | $3.32M | $2.34M | 24.9% | +45.6% |
| Software | $1.37M | $1.23M | – | – | $1.64M | $2.07M | – | – | – | – | – | – | 16.8% | -16.1% |
| Services and other | $478.00K | $593.00K | $456.00K | $433.00K | $423.00K | $453.00K | $514.00K | $52.00K | $1.26M | $1.94M | $2.51M | $2.86M | 5.8% | +13.0% |
| Software | – | – | – | $1.54M | $1.64M | $2.07M | – | $1.27M | $1.68M | $1.75M | – | $1.64M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMEA | $4.84M | $3.55M | $4.18M | $3.63M | $3.23M | $3.07M | $4.71M | $2.76M | $3.62M | $3.13M | $4.54M | $2.69M | 59.2% | +50.0% |
| Americas | $3.02M | $2.49M | $3.35M | $2.85M | $2.93M | $3.06M | $3.04M | $2.54M | $3.39M | $4.69M | $4.92M | $5.35M | 37.0% | +3.3% |
| Asia Pacific | $307.00K | $641.00K | $418.00K | $890.00K | $579.00K | $333.00K | $414.00K | $772.00K | $761.00K | $946.00K | $1.27M | $1.29M | 3.8% | -47.0% |
From the segment and revenue-disaggregation notes of Bionano Genomics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.